DOI: https://dx.doi.org/10.18565/pharmateca.2022.1.100-103
А.А. Камалова (1, 2), М.И. Исмагилова (2), Г.А. Гарина (1), А.Н. Бадретдинова (1), Л.М. Зиятдинова (2)
1) Казанский государственный медицинский университет, кафедра госпитальной педиатрии, Казань, Россия; 2) Детская республиканская клиническая больница, изоляционно-диагностическое отделение, Казань, Россия
1. Mori F., Caffarelli C., Cammi S., et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) Acta Biomed 2019;90(Suppl. 3):66–79. Doi: 10.23750/abm.v90i3-S.8167. 2. Kani Y., Shiohara T. The variable clinical picture of druginduced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am. 2009;29:481–501. Doi: 10.1016/j.iac.2009.04.007. 3. Kardaun S.H., Sekula P., Valeyrie-Allanore L., et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–80. Doi: 10.1111/bjd.12501. 4. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Allergol Select. 2017;4;1:96–1084. Doi: 10.5414/ALX01508E. 5. Choudhary S., McLeod M., Torchia D., Romanelli P. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. J Clin Aesthet Dermatol. 2013;6:31–7. 6. Um S.J., Lee S.K., Kim Y.H., et al. Clinical features of drug induced hypersensitivity syndrome in 38 patients. J Investig Allergol Clin Immunol. 2010;20:556–62. 7. Husain Z., Reddy B.Y., Schwartz R.A. DRESS syndrome: Part II. Management therapeutics. J Am Acad Dermatol. 2013;68:709.e1–9. Doi: 10.1016/j.jaad.2013.01.032.
Автор для связи: Аэлита Асхатовна Камалова, д.м.н., профессор кафедры госпитальной педиатрии, Казанский государственный медицинский университет, Казань, Россия; aelitakamalova@gmail.com ORCID / eLibrary SPIN:
А.А. Камалова, https://orcid.org/0000-0002-2957-680X; eLibrary SPIN:3922-1391
Г.А. Гарина, https://orcid.org/0000-0002-4333-8779